Table 2 Levels of health status dimensions in patients with RA examined cross-sectionally in 1994, 1996, 2001 and 2004 (mean values with 95% CI)
Dimension1994 (n = 931)1996 (n = 1025)2001 (n = 829)2004 (n = 914)
Physical
    MHAQ (1–4)1.68 (1.64; 1.71)1.65 (1.62; 1.69)1.58 (1.54; 1.62)1.55 (1.51; 1.58)
    AIMS2 (0–10)2.77 (2.64; 2.90)2.75 (2.63; 2.87)2.24 (2.12; 2.36)2.01 (1.90; 2.12)
    SF-36 physical (0–100)48.5 (46.8; 50.2)48.8 (47.1; 50.4)52.4 (50.6; 54.2)54.5 (52.8; 56.2)
    SF-36 PCS (0–100)31.4 (30.7; 32.2)32.0 (31.3; 32.7)32.7 (31.9; 33.5)33.7 (32.9; 34.4)
Pain
    VAS (0–100)46.0 (44.4; 47.5)37.7 (36.2; 39.1)35.8 (34.1; 37.4)34.5 (33.0; 36.1)
    AIMS2 (0–10)5.41 (5.24; 5.58)5.20 (5.04; 5.36)4.96 (4.78; 5.14)4.69 (4.52; 4.86)
    SF-36 (0–100)41.2 (39.8; 42.7)43.0 (41.6; 44.4)43.6 (42.1; 45.1)44.6 (43.3; 45.9)
Fatigue
    VAS (0–100)50.0 (48.2; 51.8)44.1 (42.3; 45.9)46.9 (44.9; 48.9)46.1 (44.2; 48.1)
    SF-36 (0–100)39.8 (38.3; 41.3)41.6 (40.2; 42.9)42.2 (40.6; 43.7)42.5 (41.1; 43.9)
Global
    VAS (0–100)48.5 (47.0; 50.0)44.8 (43.5; 46.2)39.8 (38.1; 41.6)38.2 (36.6; 39.8)
    AIMS2 impact (0–10)4.61 (4.43; 4.79)4.28 (4.12; 4.44)3.97 (3.80; 4.15)3.66 (3.49; 3.84)
    SF-36 (0–100)42.1 (40.6; 43.5)43.7 (42.3; 45.1)45.1 (43.6; 46.6)47.8 (46.4; 49.4)
Mental
    AIMS2 affect (0–10)3.28 (3.16; 3.40)3.41 (3.29; 3.53)3.29 (3.17; 3.41)3.07 (2.96; 3.18)
    SF-36 (0–100)68.2 (66.8, 69.6)68.6 (67.3; 69.9)70.6 (69.2; 72.0)70.8 (69.5; 72.1)
    SF-36 MCS (0–100)46.3 (45.5; 47.2)45.3 (44.5; 46.0)47.0 (46.2; 47.9)47.5 (46.7; 48.3)
Social
    AIMS2 (0–10)4.28 (4.17; 4.39)4.24 (4.14; 4.35)4.05 (3.94; 4.16)4.01 (3.91; 4.11)
    SF-36 (0–100)64.4 (62.5; 66.2)64.2 (62.4; 66.0)66.8 (64.9; 68.7)70.6 (68.8; 72.3)
Role
    SF-36 physical (0–100)27.9 (25.5; 30.2)26.6 (24.4; 28.8)30.4 (27.8; 33.0)34.1 (31.6; 36.6)
    SF36 mental role (0–100)52.0 (49.3; 54.7)47.9 (45.4; 50.4)56.2 (53.2; 59.1)59.3 (56.6; 62.0)
Utility
    SF-6D (0–1)0.616 (0.607; 0.625)0.617 (0.608; 0.625)0.639 (0.629; 0.649)0.647 (0.638; 0.656)
Coping
    Self-efficacy symptoms (10–100)62.1 (60.6; 63.4)NA63.9 (62.5; 65.2)70.4 (68.8; 71.9)
    Self-efficacy pain (10–100)52.8 (51.5; 54.1)NA52.2 (55.9; 53.6)54.8 (53.6; 56.0)
  • AIMS2, Arthritis Impact Measurement Scales 2; MCS, mental component summary (scores); MHAQ, Modified Health Assessment Questionnaire; NA, not assessed; PCS, physical component summary (score); VAS, visual analogue scale.

  • Significant improvement compared with 1994 (non-overlapping confidence intervals) is indicated in italics.

  • SF-36 (100 = best).